Underweight BKNG to 60-70% benchmark weight with trim into $213-218 zone pending Q3 catalyst
Three-point analytical convergence drives Underweight over Hold: (1) ALL three analysts — including the structurally bullish Conservative who correctly defends the compounder thesis ($9B FCF, 34.5% operating margins, $17B cash, 0.3x net leverage) — agree near-term setup has worsened; (2) Research Manager's documented evidence is dispositive — H1 2026 capital returns ($8.42B) exceeded FCF ($6.75B) by 25%, net debt jumped 94% QoQ to $2.97B, revenue growth decelerated to 8.1% with management trimming guidance — the "self-funding fortress" narrative is no longer accurate; (3) The trader's SELL order structure ($215 sell / $225 stop) is mechanically inconsistent — the Neutral Analyst correctly identified this describes a short, not a protective stop on a long trim. Execution discipline: wait for $213-218 zone rather than selling at current $209 (Conservative correctly notes selling ahead of seasonally strongest quarter with Q3 print six weeks out risks missing upside). Hard invalidation at close <$195 changes thesis from trim to exit.
| Position | Action |
|---|---|
| Current positioning | 60-70% benchmark weight (underweight) |
| Rallies into $213-218 zone (failed breakout supply) | Trim 25-30% of existing exposure — NOT at current levels, NOT at open |
| Confirmed close <$207.34 with expanding volume | Secondary trim trigger toward $190-195 test (50 SMA / 200 SMA) |
| Close <$195 | Exit thesis entirely — changes from trim to exit (buyback mechanical bid concentrates at 50/200 SMA cluster $185-190) |
| Q3 sub-8% revenue print or another guide-down | Trim toward 50% benchmark weight |
BKNG is a mispriced $157B market-cap compounder trading at 16.9x forward earnings with a 0.92 PEG ratio, generating $9B+ in annual FCF and sitting on $10B in pre-booked deferred revenue, making the recent laggard label an opportunity rather than a warning sign.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 185.35 | bullish |
| 50 SMA | 190.71 | bullish |
| 10 EMA | 210.14 | bearish |
| RSI(14) | 57.39 | neutral |
| MACD | 6.38 | neutral |
| MACD Histogram | -0.91 | bearish |
| ATR(14) | 6.69 | neutral |
| Bollinger Middle Band (20 SMA) | 207.34 | neutral |
| Bollinger Upper Band | 222.68 | neutral |
| Bollinger Lower Band | 192.01 | neutral |
| Price Close |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close >$215.69 on volume >7M shares coinciding with Q3 print validating deferred revenue
Then: Re-assess for re-engagement (would NOT be stop-out scenario)
↩ rebuts: “Bear overreaction to guidance trim”
EV: $250-$260 over 12 months · concedes: Guide trim is real (though FX/macro-cautious rather than demand-driven); Index underperformance is real but irrelevant to intrinsic value; Google/AI structural threat is genuine but not imminent; Near-term technical consolidation is normal post-rally
BKNG is a decelerating compounder priced at a premium multiple with a structurally broken buyback program, failing technicals, and asymmetric downside risk that outweighs the upside case.
EV: $175-185 (bear case over 6 months if Q3 disappoints); HOLD or REDUCE at current levels · concedes: BKNG is a well-run franchise with a durable moat; Cash flow and capital return programs have been historically shareholder-friendly; Not all deferred revenue is FX-inflated or at risk
→ vs conservative: The $9B FCF, 16.9x forward PE, and PEG of 0.92 make BKNG a value trap at current prices — compounding only works if you buy at the right price, and at $209 you're paying full price for deteriorating fundamentals
→ vs conservative: The $10.1B deferred revenue growth (11% YoY) is not a margin leading indicator — trimmed guidance shows bookings on the books won't translate at assumed unit economics
→ vs conservative: BKNG trimmed guidance while ABNB raised guidance and hit a four-year high — betting on the loser of a two-horse race while calling it a compounder
→ vs neutral: Waiting for $215.69 breakout or $207.34 breakdown means buying the eventual breakdown bounce and selling the eventual dead-cat bounce — how you underperform by 3-4% per year forever
→ vs neutral: MACD histogram 'fading momentum', RSI 'healthy digestion', and lower-high pattern translate to momentum rolling over, not a coiled spring — spring is losing tension
| 208.89 |
| neutral |
Support: 207.34 · 192.01 · 190.71 | Resistance: 210.14 · 215.69 · 222.68
BKNG completed a 25:1 stock split on 2026-04-06 and recovered aggressively from a May 15, 2026 intraday low of $152.67 to an August 7, 2026 high of $215.69 before entering a 13-session consolidation. The long-term trend remains bullish with both the 50 SMA ($190.71) and 200 SMA ($185.35) rising and price 9.5% and 12.7% above them respectively, with the 50 SMA already above the 200 SMA. Short-term weakness is evident as price closed below the 10 EMA ($210.14) for two consecutive sessions and the MACD histogram turned negative (-0.91), indicating fading momentum. Immediate support is at the Bollinger middle band ($207.34), with deeper support at $192.01 (lower band) and the 50 SMA ($190.71); resistance is at $210.14 (10 EMA) and the August 7 high ($215.69), above which the next target is the Bollinger upper band at $222.68.
Market Cap
$156.96 B
TTM PE Ratio
23.21
Forward PE
16.88
PEG Ratio
0.92
Price to Book
-14.68
TTM EPS
$9.00
Forward EPS
$12.38
Dividend Yield
0.79%
Beta
1.07
52-Week High
$227.72
52-Week Low
$150.14
50-Day MA
$190.03
200-Day MA
$185.83
Current Price
~$208.90
Revenue 2025
$26,917 M
Revenue 2024
$23,739 M
Revenue 2023
$21,365 M
Revenue 2022
$17,090 M
Operating Income 2025
$9,282 M
Operating Margin 2025
34.5%
Operating Margin 2024
31.8%
Net Income 2025
$5,404 M
Net Income 2024
$5,882 M
Diluted EPS 2025
$6.62
Diluted EPS 2024
$6.91
Diluted EPS 2023
$4.70
Diluted Shares 2025
816 M
Diluted Shares 2022
1,001 M
Diluted Shares Q2 2026
770 M
Q2 2026 Revenue
$7,352 M
Q2 2026 Revenue YoY Growth
+8.1%
Q2 2026 Operating Income
$2,500 M
Q2 2026 Operating Margin
34.0%
Q2 2026 Net Income
$1,950 M
Q2 2026 Diluted EPS
$2.53
Cash & ST Investments Q2 2026
$17,214 M
Cash & ST Investments FY 2025
$17,203 M
Total Debt Q2 2026
$20,694 M
Total Debt FY 2025
$19,293 M
Net Debt Q2 2026
$2,966 M
Total Equity Q2 2026
($10,783) M
Treasury Stock Q2 2026
$62,129 M
Treasury Stock FY 2025
$54,315 M
Current Ratio Q2 2026
1.09
Working Capital Q2 2026
$1,986 M
FCF 2025
$9,087 M
FCF 2024
$7,894 M
FCF 2023
$6,999 M
FCF 2022
$6,186 M
FCF Margin 2025
33.8%
CapEx 2025
($322) M
CapEx/Revenue
~1.2%
Buybacks 2025
$6,440 M
Dividends 2025
$1,248 M
Operating Cash Flow 2025
$9,409 M
Q1 2026 FCF
$3,108 M
Q2 2026 FCF
$3,643 M
Q1 2026 Buybacks
($3,770) M
Q2 2026 Buybacks
($3,988) M
1H 2026 Total Capital Returns
~$8.4 B
Deferred Revenue Q2 2026
$10.12 B
ROA
20.4%
Profit Margin
25.5%
Revenue Growth 2025 YoY
+13.4%
Revenue Growth 2024 YoY
+11.1%
Revenue 5-Year CAGR
~25%
Composite Score
8.4 / 10
Strengths
Concerns
Booking Holdings remains one of the highest-quality cash-flow stories in consumer cyclical, generating ~$9.1B in annual FCF (33.8% margin) with CapEx of only 1.2% of revenue. The company is aggressively returning capital via $6-10B/year buybacks plus a growing dividend, reducing diluted shares 23% from 1,001M (2022) to 770M (Q2 2026), driving meaningful per-share EPS compounding. Q2 2026 confirmed continued momentum with $7.35B revenue (+8.1% YoY), 34% operating margin, and $10.1B in deferred revenue signaling strong Q3 visibility. Valuation is fair-to-attractive at 16.9x forward PE with 0.92 PEG ratio. Rating: HOLD — best deployed as a long-term core holding accumulated on weakness toward $185-190 rather than traded on near-term catalysts.